Serum TRACP 5b and ICTP as markers of bone metastases in breast cancer

Anticancer Research

Volumn 26, Issue 4 B, 2006, Pages 3127-3132

  Korpela, J ^a,g   Tiitinen, S L ^b,c   Hiekkanen, H ^c   Halleen, J M ^c,d   Selander, K S ^c,e   Vaananen H K ^c   Suominen, P ^f   Helenius, H ^c   Salminen, E ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Finnish Red Cross   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d Pharmatest Services Ltd   (Finland)

^e University of Alabama at Birmingham   (United States)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g NONE   (Finland)

Author keywords

Bone metastasis markers; Breast cancer; ICTP; tALP; TRACP 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BISPHOSPHONIC ACID DERIVATIVE; CARBOXY TERMINAL TELOPEPTIDE; HORMONE; TARTRATE RESISTANT ACID PHOSPHATASE 5B; UNCLASSIFIED DRUG;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMIC THERAPY;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BONE NEOPLASMS; BREAST NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; ISOENZYMES; MIDDLE AGED; PEPTIDE FRAGMENTS; PROCOLLAGEN; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 33746724127     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Käkönen SM and Mundy GR: Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97 (suppl. 3): 834-839, 2003.
2. Coleman RE and Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61-66, 1987.
3. Diel IJ, Solomayer EF and Basiert G: Bisphosphonates and the prevention of metastasis: first evidences from preclinical and clinical studies. Cancer 88 (suppl. 12): 3080-3088, 2000.
4. Lam KW, Li CY, Yam LT and Desnick RJ: Comparison of the tartrate-resistant acid phosphatase in Gaucher's disease and leukemic reticuloendotheliosis. Clin Biochem 14: 177-181, 1981.
5. Janckila AJ, Neustadt DH, Nakasato YR, Halleen JM, Hentunen T and Yam LT: Serum tartrate-resistant acid phosphatase isoforms in rheumathoid arthritis. Clin Chem Acta 320: 49-58, 2002.
6. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ and Väänänen HK: Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 75: 1337-1345, 2000.
7. Halleen JM, Alatalo SL, Janckila AJ, Woitge HW, Seibel MJ and Väänänen HK: Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 47: 597-600, 2001.
8. Hannon RA, Clowes JA, Eagleton AC, Al Hadari A, Eastell R and Blumsohn A: Clinical performance of immunoreactive tartrate resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone 34: 187-194, 2004.
9. Halleen JM, Ylipahkala H, Alatalo SL, Jancila AJ, Heikkinen JE, Suominen H, Cheng S and Väänänen HK: Serum tartrate resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcif Tissue Int 71: 20-25, 2002.
10. Janckila AJ, Takahashi K, Sun SZ and Yam LT: Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 47: 74-80, 2001.
11. Capeller B, Caffier H, Sutterlin MW and Dietl J: Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 23: 1011-1015, 2003.
12. Koizumi M, Takahashi S and Ogata E: Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 23: 4095-4099, 2003.
13. Chao TY, Yu JC, Ku CH, Chen MM, Lee SH, Jancila AJ and Yam LT: Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Clin Cancer Res 11: 544-550, 2005.
14. Lyubimova NV, Pashkov MV, Tyulyandin SA, Goldberg VE and Kushlinskii NE: Tartrate-resistant acid phosphatase as a marker of bone metastases in patients with breast cancer and prostate cancer. Bull Exp Biol Med 138: 77-79, 2004.
15. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievänen H, Vuori I, Väänänen HK and Halleen JM: Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20: 1804-1812, 2005.
16. Koizumi M, Takahashi S and Ogata E: Bone metabolic markers in bisphosphonate therapy for skeletal metastases in patients with breast cancer. Breast Cancer 10: 21-27, 2003.
17. Terpos T, de la Fuente J, Szydlo R, Hatjiharissi E, Viniou N, Meletis J, Yataganas X, Goldman JM and Rahemtulla A: Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma. Int J Cancer 106: 455-457, 2003.
18. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A and Loukopoulos D: Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 123: 730-737, 2003.
19. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Åkesson K and Obrant KJ: Biochemical markers of bone metabolism and prediction of fracture in elderly women. J Bone Miner Res 19: 386-393, 2004.
20. Sassi ML, Eriksen H, Risteli L, Niemi S, Mansell J, Gowen M and Risteli J: Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen: loss of antigenicity by treatment with cathepsin K. Bone 26: 367-373, 2000.
21. Garnero P, Ferreras M, Karsdal MA, Nicamhlaoibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT and Delaisse JM: The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res 18: 859-867, 2003.
22. Hanley JA and McNeil BJ: The meaning and use of the area under a receiver operating characteristics (ROC) curve. Radiology 143: 29-36, 1982.
23. Hanley JA and McNeil BJ: A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148: 839-843, 1983.
24. Koizumi M, Matsumoto S, Takahashi S, Yamashita T and Ogata E: Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl Med 24: 15-20, 1999.
25. Meijer WG, van der Veer E and Willemse PH: Biochemical parameters of bone metabolism in bone metastases of solid tumors. Oncol Rep 5: 5-21, 1998.
26. Li J, Zhang Z, Rosenzweig J, Wang YY and Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-1304, 2002.